News & Media

Boston Biomedical is headquartered in Cambridge, Massachusetts, and is engaged in the discovery and development of novel oncology therapeutics. A list of recent press releases and other news from Boston Biomedical can be found below. To contact our media relations staff, click here.

Boston Biomedical Announces First Patient Dosed with Investigational Toll-like Receptor (TLR) 7 Agonist DSP-0509 in Phase 1 Trial of Patients with Advanced Solid Tumors Refractory to Standard Treatment
09/13/2018 

Boston Biomedical, Inc., a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes, today announced that it has initiated clinical trial activities for DSP-0509, an investigational Toll-like receptor (TLR) 7 agonist.

Read More

Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018
06/01/2018 

Boston Biomedical, Inc., an industry leader in the development of novel cancer therapeutics, today announced that it will present new research evaluating investigational compound napabucasin in the treatment of multiple cancers, including metastatic pancreatic adenocarcinoma, advanced gastric and gastroesophageal junction adenocarcinoma, and advanced thymoma and thymic carcinoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from June 1-5. The company will also present background on a clinical study evaluating investigational compound DSP-7888 for the treatment of glioblastoma, which recently began enrolling patients.

Read More

Boston Biomedical, Inc. Announces Presentations for Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) to be Featured at ASCO 2018
05/17/2018 

Boston Biomedical, Inc., an industry leader in the development of novel cancer therapeutics, today announced that it will feature several studies evaluating investigational compounds napabucasin and DSP-7888 at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from June 1-5.

Read More

Boston Biomedical Inc. Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*)
04/25/2018 

CAMBRIDGE, Mass., April 25, 2018 – Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced that it has initiated dosing of the first patient in each of two clinical studies evaluating DSP-7888, an investigational cancer peptide vaccine. One study is in combination with checkpoint inhibitors for multiple tumor types, and the other is in combination with bevacizumab in glioblastoma. DSP-7888 is hypothesized to induce Wilms’ tumor gene 1 (WT1)-specific cytotoxic T lymphocytes (CTL) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic cancers and solid tumors. WT1 has been a focus of cancer vaccine researchers since the National Cancer Institute ranked it as the number one priority target for cancer immunotherapy.[i]

Read More

Boston Biomedical, Inc. Appoints Edgar Braendle, M.D., Ph.D., as Head of Research and Development and Chief Medical Officer
10/16/2017 

Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced the appointment of Edgar Braendle, M.D., Ph.D., to Executive Vice President, Head of Research and Development and Chief Medical Officer. Dr. Braendle will lead the company's discovery research and clinical strategies.

Read More

Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer
10/10/2017 

Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for DSP-7888, an investigational cancer peptide vaccine, for the treatment of brain cancer. This is the second ODD for DSP-7888 this year. The first was granted in June 2017 for myelodysplastic syndrome

Read More

Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome
07/10/2017 

CAMBRIDGE, Mass., July 10, 2017 /PRNewswire/ -- Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for DSP-7888, an investigational cancer peptide vaccine, for the treatment of myelodysplastic syndrome (MDS). MDS is a group of rare blood disorders characterized by abnormal development of blood cells within the bone marrow.1

Read More

Boston Biomedical Presents Data for Investigational Cancer Stemness Inhibitor Napabucasin in Metastatic Colorectal and Pancreatic Cancer at ESMO GI 2017
06/30/2017 

Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, featured two oral and two poster presentations evaluating napabucasin in metastatic colorectal cancer (mCRC) and pancreatic adenocarcinoma (mPDAC) at the European Society of Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer, held from June 28 to July 1 in Barcelona, Spain. Napabucasin is an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3. The abstracts were simultaneously published in the ESMO GI 2017 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Read More

Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer
06/26/2017 

Boston Biomedical, Inc., today announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin plus paclitaxel versus paclitaxel alone for patients with advanced gastric/GEJ (gastroesophageal junction) cancer will be unblinded. This decision is based on a recommendation by the trial's Data and Safety Monitoring Board (DSMB), following a pre-specified interim analysis on two-thirds of the total planned events. The DSMB determined that the study was unlikely to reach its primary endpoint of superior overall survival for napabucasin plus paclitaxel versus paclitaxel alone. No safety concerns were identified by the DSMB. Boston Biomedical has accepted this recommendation to unblind the study and plans to continue to follow all endpoints as defined in the protocol. Boston Biomedical will communicate further details to investigators shortly.

Read More

Boston Biomedical, Inc. Chief Executive Officer Patricia S. Andrews Appointed to Board of Directors of GlycoMimetics
06/12/2017 

Boston Biomedical, Inc. Chief Executive Officer Patricia S. Andrews has been appointed to the board of directors of GlycoMimetics, Inc. (NASDAQ: GLYC). This appointment reflects Ms. Andrews’ position as an industry leader in the oncology field and the value of her extensive commercial experience, leading multiple companies through the transition from R&D to commercial-stage, and successfully launching first-in-class oncology products. Her contributions at leading oncology-focused companies – Boston Biomedical, Inc., Incyte and Pfizer – have been instrumental in building a high performing organization and preparation for the successful commercialization of the company’s assets.

Read More

Boston Biomedical Presents Data for Investigational Stemness Inhibitor Amcasertib at ASCO 2017
06/05/2017 

CAMBRIDGE, Mass., June 5, 2017 /PRNewswire/ -- Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, will present data today from a phase 1b/2 study evaluating amcasertib monotherapy in two solid tumor subpopulations – advanced adenoid cystic carcinoma (ACC) and advanced head and neck cancers – at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Amcasertib is an orally-administered investigational agent designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases.

Read More

Boston Biomedical Presents Data Suggesting Anti-Cancer Activity of Investigational Stemness Inhibitor Napabucasin in Seven Tumor Types at ASCO 2017
06/03/2017 

Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, will present phase 1b/2 clinical data evaluating napabucasin, an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Presented today and tomorrow (June 4), these study results show anti-cancer activity in advanced or metastatic disease in seven tumor types: colorectal cancer (mCRC), pancreatic cancer (mPDAC), non-squamous non-small cell lung cancer, ovarian cancer, breast cancer, hepatocellular cancer, and melanoma.

Read More

Boston Biomedical Announces Presentations for Investigational First-in-Class Cancer Stemness Inhibitors Napabucasin and Amcasertib in Multiple Tumor Types at ASCO 2017
05/18/2017 

CAMBRIDGE, Mass., May 18, 2017 /PRNewswire/ -- Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, today announced it will feature 11 clinical data poster presentations on investigational compounds evaluating napabucasin and amcasertib in nine different tumor types at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 2-6, in Chicago.

Read More

Featured in P&T Community: Napabucasin’s Potential for Treating Advanced Colorectal Cancer
05/02/2017 

P&T Community, a print and online publication that reports on drug forecasts and analysis for a target audience of pharmacy and therapeutic committee members, recently published an in-depth article in the April 2017 issue exploring investigational therapies in development for the treatment of advanced colorectal cancer (CRC).

Read More

Featured in OncLive: Dr. O'Neil on Stemness Inhibitors for CRC Treatment
05/01/2017 

OncLive, an oncology-focused print and online trade media outlet, recently posted an interview with Bert O’Neil, M.D. about the emerging role of stemness inhibitors for the treatment of metastatic colorectal cancer (mCRC).

Read More

Boston Biomedical Presents New Preclinical Data at AACR 2017 Highlighting the Potential Role of Cancer Stemness Inhibition
04/04/2017 

Boston Biomedical, an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, presented preclinical data from its research and development portfolio at the 2017 American Association for Cancer Research (AACR) Annual Meeting held from April 1-5, in Washington, D.C.

Read More

Boston Biomedical Celebrates 10-Year Anniversary of its Founding and Announces Appointment of Patricia S. Andrews as Chief Executive Officer
03/22/2017 

Boston Biomedical, an industry leader in the development of next-generation cancer therapeutics designed to target cancer stemness pathways, today announced its Board of Directors has appointed Patricia S. Andrews as Chief Executive Officer, effective April 24, 2017.

Read More

Boston Biomedical to Present Preclinical Data on Targeting Cancer Stemness at AACR 2017
03/09/2017 

CAMBRIDGE, Mass. March 9, 2017 – Boston Biomedical, an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, will present data from six preclinical studies – including five late-breaking posters – from its research and development portfolio at the upcoming 2017 American Association for Cancer Research (AACR) Annual Meeting held from April 1-5, in Washington, D.C.

Read More

Boston Biomedical Initiates CanStem111P: A Global Phase 3 Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Metastatic Pancreatic Cancer
02/21/2017 

Boston Biomedical, an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, has initiated dosing of the first patient in a new global phase 3 study, CanStem111P. The study will investigate napabucasin – an orally administered, first-in-class, investigational agent designed to inhibit cancer stemness pathways by targeting STAT3 – in combination with standard of care (nab-paclitaxel plus gemcitabine) in patients with metastatic pancreatic cancer.

Read More

Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI Symposium
01/21/2017 

CAMBRIDGE, Mass. January 21, 2017 – Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, today presented data from two clinical studies for its lead investigational compound, napabucasin, at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.

Read More

Boston Biomedical to Highlight Data for Cancer Stemness Inhibitor Napabucasin in Patients with Colorectal Cancer at 2017 ASCO GI
01/18/2017 

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, will feature data from two clinical studies for its lead investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in San Francisco.

Read More